MabVax Therapeutics Sends Letter to Holders Following Uplisting to NASDAQ

Highlights of the letter include: Discussion of MabVax's recent accomplishments that have met previously announced timelines for clinical and corporate development. The uplisting of its shares onto the Nasdaq Capital Market and equity research initiation by Laidlaw & Company The Company's current status of its clinical development pipeline and updates on significant near-term milestones for MVT-5873, MVT-2163, and MVT-1075, and work on its emerging pipeline of new human antibody candidates. Review of the Company's ongoing collaborations and partnering discussions that include Memorial Sloan Kettering Cancer Center, Rockefeller University and Heidelberg Pharma. Review of its investment focus that enables MabVax to advance its product programs towards important near-term clinical development milestones.